Kriya Therapeutics, a gene therapy biotech with operations in North Carolina and California, secured $313 million in a recent funding round to accelerate its development of gene therapies targeting serious diseases. This sizable capital infusion demonstrates strong investor confidence in gene editing and delivery technologies aimed at transforming treatment paradigms for various genetic conditions.